[Clinical study of shengxue mixture in treating aplastic anemia].
To observe the clinical effect of Shengxue mixture (SXM) in treating aplastic anemia, and studied its mechanism. Eighty-four patients of the treated group, those with Spleen-Kidney Yang deficiency Syndrome and Spleen-Kidney Yin deficiency Syndrome were treated with SXM-A and SXM-B respectively, and 30 patients of the control group were treated with Stanozolol. The clinical effect and several experimental parameters were also observed. The basic cure rate, remission rate, total effective rate of the treated and control group were 21.43%, 27.38%, 86.90% and 3.33%, 20.00%, 56.67% respectively, the difference between 2 groups was significant (P < 0.05, P < 0.01). The effect of the treated group was obviously better than that of the control group. While the patients' symptoms were alleviated, the peripheral blood cells increased, the ratio of T lymphocyte subsets tended to balance, the level of natural killer cells activity increased, interleukin 2 reduced, and the reproduction of the bone marrow were markedly improved in most of the patients treated by SXM. SXM is an effective and safe drug for aplastic anemia. Its mechanism might be regulating the immune function, which facilitated the recovery of the bone marrow hematopoiesis function.